ClinicalTrials.gg
CompletedNCT02142049Updated Feb 5, 2019Results posted

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

A Phase 1/2 interventional study of Ibrutinib and DA-EPOCH-R in Diffuse Large B Cell Lymphoma Relapsed and Diffuse Large B Cell Lymphoma Refractory, sponsored by Pharmacyclics LLC.. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-05.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing ibrutinib in Lymphoma — 2 open to participants now, 4 under way, none of them phase 3. ibrutinib · Lymphoma.

Enrollment
13th of 19
35 · median 80
Started
2014
with 2 others
Phase 1/2
5 of 19
1 open now
Registered
8th of 19
by date
Lead sponsor
6 of 19
Pharmacyclics LLC.

Among the 19 studies testing ibrutinib in Lymphoma, this one is the 13th largest by enrollment, is one of 3 that started in 2014, is one of 5 in phase 1/2, and was the 8th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

2 of the 19 studies testing ibrutinib in Lymphoma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing ibrutinib in Lymphoma, or all of them as a file.
02

Study summary

This is a Phase 1b/2, open-label, non-randomized multicenter study to assess the safety and efficacy of ibrutinib and lenalidomide in combination with DA-EPOCH-R in subjects with relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL).

Read the detailed description

This is a Phase 1b, open-label, non-randomized multicenter study conducted in 2 parts. Part 1, will determine the MTD of the combination of ibrutinib, lenalidomide and DA-EPOCH-R in subjects with DLBCL.

Ibrutinib will be administered at a fixed dose of 560 mg and lenalidomide will be dose-escalated. DA-EPOCH-R will be given at standard doses.

For Part 2, the MTD determined in Part 1 will be the dose used for all subjects. If no MTD is identified, then subjects in Part 2 will be treated with the maximum administered doses (MAD, treatment doses from dose Level 4).

The primary objective for Part 2 is to determine the ORR of ibrutinib and lenalidomide in combination with DA-EPOCH-R in subjects with ABC DLBCL as analyzed by gene expression profiling when treated at recommended phase 2 dose (RP2D).

03

Conditions studied

  • Diffuse Large B Cell Lymphoma Relapsed
  • Diffuse Large B Cell Lymphoma Refractory

Browse trials for

Keywords

  • DLBCL
  • ABC
  • GCB
  • Primary Mediastinal B-cell lymphoma
  • Pharmacyclics
  • Lenalidomide
  • lymphoma
  • Rituximab
  • EPOCH
  • Recommended Phase 2 Dose(RP2D)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major inclusion criteria:

  • (ECOG) performance status of ≤2
  • confirmed DLBCL
  • Subjects must have ≥1 site on CT scan (≥ 1.5 cm in longest dimension).
  • Adequate hepatic and renal function:

    • or ALT ≤2.5 x
    • Serum Creatinine ≤ 2.0 mg/dL and ≥60 mL/min/1.73
    • ≤1.5 x ULN
  • Adequate hematologic function:

    • >1,000 cells/mm3
    • ≥75,000 cells/mm3
    • ≥8.0 g/dL
    • (PT) and activated partial thromboplastin time (aPTT) must be ≤1.5 x the upper limit of the normal range (ULN)
  • Must be registered into the Revlimid REMS™program and be willing to comply with the requirements of Revlimid REMS™.

Major Exclusion Criteria:

  • Known central nervous system lymphoma
  • Any chemotherapy, external beam radiation therapy, or anti-cancer antibodies within 2 weeks
  • Radio- or toxin-immunoconjugates within 10 weeks
  • Prior allogenetic stem cell (or other organ) transplant within 6 months or any evidence of active or requirement for within 28 days prior to first dose of study drug
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Part 1: Dose Level 1

    Ibrutinib 560 mg PO + DA-EPOCH-R

    Drug: Ibrutinib · Drug: DA-EPOCH-R

  • Experimental
    Part 1: Dose Level 2

    Ibrutinib 560 mg (PO) +lenalidomide 15 mg (PO) + DA-EPOCH-R

    Drug: Ibrutinib · Drug: DA-EPOCH-R · Drug: Lenalidomide

  • Experimental
    Part 1: Dose Level 3

    Ibrutinib 560 mg (PO) +lenalidomide 20 mg (PO) + DA-EPOCH-R

    Drug: Ibrutinib · Drug: DA-EPOCH-R · Drug: Lenalidomide

  • Experimental
    Part 1: Dose Level 4

    Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R

    Drug: Ibrutinib · Drug: DA-EPOCH-R · Drug: Lenalidomide

  • Experimental
    Part 2: RP2D

    Recommended Phase 2 Dose(RP2D): Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R

    Drug: Ibrutinib · Drug: DA-EPOCH-R · Drug: Lenalidomide

Interventions

  • Ibrutinib

  • DrugDA-EPOCH-R

    Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim

  • Lenalidomide

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability

    Part-1: To determine the maximum tolerated dose (MTD) of the combination of ibrutinib and lenalidomide with dose adjusted EPOCH-R

    Time frame: 1 year after last subjects received the first dose

  2. Number of Participants With Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy-ORR

    Part 2 - Overall Response rate will be defined as the proportion of subjects who achieve either a Complete Response or a Partial Response according to the international Working Group Response Criteria for NHL as assessed by investigator.

    Time frame: 1 year after last subjects received the first dose

Secondary outcomes

  1. Number of Participants With Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy

    Part-1: Overall Response rate (ORR) will defined as the proportion of subjects who achieve either a CR or a PR according to the international Working Group Response Criteria for NHL as assessed by investigator.

    Time frame: 1 year after last subjects received the first dose

  2. Number of Subjects With Adverse Events as a Measure of Safety and Tolerability

    Part 2: The frequency (number and percentage) of treatment-emergent adverse events will be reported.

    Time frame: 1 year after last subjects received the first dose

  3. Progression Free Survival (PFS) and Overall Survival (OS) as a Measure of Efficacy

    Part 2: PFS will be measured as time from first study drug administration to disease progression or death from any cause. OS will be measured from the time of first study drug administration until the date of death using Kaplan-Meier methodology.

    Time frame: From initial dose date until the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 1 year after the last subject received the first dose, up to 36 months at the most.

  4. Duration of Response (DOR)

    Part 2: DOR will be measured from the time by which the measurement criteria are met for CR or PR until the first date by which recurrent or progressive disease is objectively documented.

    Time frame: From initial response date until the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 1 year after the last subject received the first dose.

07

Results

Posted Feb 5, 2019

Participant flow

Participant flow — Overall Study
MilestonePart 1: Dose Level 1Part 1: Dose Level 2Part 1: Dose Level 3Part 1: Dose Level 4Part 2: RP2D
Started333620
Completed333620
Not completed00000

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability

Part-1: To determine the maximum tolerated dose (MTD) of the combination of ibrutinib and lenalidomide with dose adjusted EPOCH-R

Time frame:
1 year after last subjects received the first dose
Reported as:
Count of participants · Participants
Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability
ParticipantsPart 1: Dose Level 1Part 1: Dose Level 2Part 1: Dose Level 3Part 1: Dose Level 4Part 1: All Treated
Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability00011
PrimaryNumber of Participants With Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy-ORR

Part 2 - Overall Response rate will be defined as the proportion of subjects who achieve either a Complete Response or a Partial Response according to the international Working Group Response Criteria for NHL as assessed by investigator.

Time frame:
1 year after last subjects received the first dose
Reported as:
Count of participants · Participants
Number of Participants With Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy-ORR
ParticipantsAll Subjects Treated at RP2DABC Subjects Treated at RP2D
Number of Participants With Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy-ORR169
SecondaryNumber of Participants With Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy

Part-1: Overall Response rate (ORR) will defined as the proportion of subjects who achieve either a CR or a PR according to the international Working Group Response Criteria for NHL as assessed by investigator.

Time frame:
1 year after last subjects received the first dose
Reported as:
Count of participants · Participants
Number of Participants With Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy
ParticipantsPart 1: Dose Level 1Part 1: Dose Level 2Part 1: Dose Level 3Part 1: Dose Level 4Part 1: All Treated
Number of Participants With Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy12036
SecondaryNumber of Subjects With Adverse Events as a Measure of Safety and Tolerability

Part 2: The frequency (number and percentage) of treatment-emergent adverse events will be reported.

Time frame:
1 year after last subjects received the first dose
Reported as:
Count of participants · Participants
Number of Subjects With Adverse Events as a Measure of Safety and Tolerability
ParticipantsAll Subjects Treated at RP2DABC Subjects Treated at RP2D
Number of Subjects With Adverse Events as a Measure of Safety and Tolerability2614
SecondaryProgression Free Survival (PFS) and Overall Survival (OS) as a Measure of Efficacy

Part 2: PFS will be measured as time from first study drug administration to disease progression or death from any cause. OS will be measured from the time of first study drug administration until the date of death using Kaplan-Meier methodology.

Time frame:
From initial dose date until the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 1 year after the last subject received the first dose, up to 36 months at the most.
Reported as:
Median · Months
Progression Free Survival (PFS) and Overall Survival (OS) as a Measure of Efficacy
MonthsAll Subjects Treated at RP2DABC Subjects Treated at RP2D
Progression Free Survival (PFS)4.86 (0.03 to 12.45)4.86 (0.03 to 9.69)
Overall Survival (OS)15.84 (0.26 to 28.22)15.84 (0.26 to 28.22)
SecondaryDuration of Response (DOR)

Part 2: DOR will be measured from the time by which the measurement criteria are met for CR or PR until the first date by which recurrent or progressive disease is objectively documented.

Time frame:
From initial response date until the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 1 year after the last subject received the first dose.
Reported as:
Median · Months
Duration of Response (DOR)
MonthsAll Subjects Treated at RP2D Who Achieved Overall ResponseABC Subjects Treated at RP2D Who Achieved Overall Response
Duration of Response (DOR)3.94 (0.03 to 10.48)4.09 (0.03 to 7.69)

Adverse events

Collected over 3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Dose Level 13/3 (100%)3/3 (100%)3/3 (100%)
Part 1: Dose Level 23/3 (100%)3/3 (100%)3/3 (100%)
Part 1: Dose Level 33/3 (100%)3/3 (100%)3/3 (100%)
Part 1: Dose Level 45/6 (83.3%)5/6 (83.3%)6/6 (100%)
All Subjects Treated at RP2D3/26 (11.5%)19/26 (73.1%)26/26 (100%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventPart 1: Dose Level 1Part 1: Dose Level 2Part 1: Dose Level 3Part 1: Dose Level 4All Subjects Treated at RP2D
Febrile neutropeniaBlood and lymphatic system disorders1/31/31/30/66/26
AnaemiaBlood and lymphatic system disorders0/30/31/32/62/26
ThrombocytopeniaBlood and lymphatic system disorders1/30/31/30/61/26
Atrial fibrillationCardiac disorders0/31/31/30/61/26
Gastrointestinal haemorrhageGastrointestinal disorders0/30/31/30/60/26
VomitingGastrointestinal disorders1/30/30/30/61/26
DeathGeneral disorders1/30/30/30/60/26
PneumoniaInfections and infestations0/31/30/30/62/26
Pneumococcal sepsisInfections and infestations0/31/30/30/60/26
Septic shockInfections and infestations1/30/30/30/60/26
Most frequent other events
Showing 10 of 163
Most frequent other events
EventPart 1: Dose Level 1Part 1: Dose Level 2Part 1: Dose Level 3Part 1: Dose Level 4All Subjects Treated at RP2D
AnaemiaBlood and lymphatic system disorders3/33/32/34/612/26
ThrombocytopeniaBlood and lymphatic system disorders3/31/31/33/612/26
Sinus tachycardiaCardiac disorders0/33/31/33/66/26
NauseaGastrointestinal disorders1/33/31/35/612/26
ConstipationGastrointestinal disorders1/33/32/33/611/26
FatigueGeneral disorders2/33/31/35/613/26
Oedema peripheralGeneral disorders1/33/33/32/67/26
DizzinessNervous system disorders1/33/32/33/68/26
DyspnoeaRespiratory, thoracic and mediastinal disorders0/33/30/31/61/26
HypotensionVascular disorders0/33/31/33/66/26

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part 1: Dose Level 1Part 1: Dose Level 2Part 1: Dose Level 3Part 1: Dose Level 4Part 2: RP2DTotal
<=18 years000000
Between 18 and 65 years13161122
>=65 years2020913
Age, Continuous
Age, Continuous(years)Part 1: Dose Level 1Part 1: Dose Level 2Part 1: Dose Level 3Part 1: Dose Level 4Part 2: RP2DTotal
Median69 (54 to 89)58 (41 to 61)67 (58 to 68)55 (38 to 61)59 (28 to 79)58 (28 to 89)
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Dose Level 1Part 1: Dose Level 2Part 1: Dose Level 3Part 1: Dose Level 4Part 2: RP2DTotal
Female010179
Male32351326
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Dose Level 1Part 1: Dose Level 2Part 1: Dose Level 3Part 1: Dose Level 4Part 2: RP2DTotal
Hispanic or Latino000000
Not Hispanic or Latino33361732
Unknown or Not Reported000033
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Dose Level 1Part 1: Dose Level 2Part 1: Dose Level 3Part 1: Dose Level 4Part 2: RP2DTotal
American Indian or Alaska Native000000
Asian010012
Native Hawaiian or Other Pacific Islander000000
Black or African American000022
White32361529
More than one race000000
Unknown or Not Reported000022
Region of Enrollment
Region of Enrollment(participants)Part 1: Dose Level 1Part 1: Dose Level 2Part 1: Dose Level 3Part 1: Dose Level 4Part 2: RP2DTotal
United States33362035
08

Study locations

10 sites
  • SITE-1
    Duarte, California 91010, United States
  • SITE-2
    Los Angeles, California 90095, United States
  • SITE-10
    Orange, California 92868, United States
  • SITE-3
    Chicago, Illinois 60612, United States
  • SITE-5
    Baltimore, Maryland 21201, United States
  • SITE-6
    Bethesda, Maryland 20892, United States
  • SITE-4
    Ann Arbor, Michigan 48109, United States
  • SITE-8
    Albuquerque, New Mexico 87106, United States
  • SITE-9
    Stony Brook, New York 11794, United States
  • SITE-7
    Charleston, South Carolina 29425, United States
09

References and documents

Publications

  • Wilson WH, Phillips T, Popplewell L, de Vos S, Chhabra S, Kimball AS, Beaupre D, Huang DW, Wright G, Kwei K, Ping J, Neuenburg JK, Staudt LM. Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2021 Sep;62(9):2094-2106. doi: 10.1080/10428194.2021.1907371. Epub 2021 Apr 15. PubMed 33856277 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Aug 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2019, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2014
First posted
May 20, 2014
Start
May 2014
Primary completionActual
Aug 2017
CompletionActual
Aug 2017
Results first posted
Feb 5, 2019
Last update
Feb 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02142049
Lead sponsor
Pharmacyclics LLC.
Collaborators
Celgene Corporation
Responsible party
Sponsor
First posted
May 20, 2014
Start date
May 2014
Primary completion
Aug 2017
Completion
Aug 2017
Results posted
Feb 5, 2019
Last update
Feb 5, 2019

Study contacts

Jutta Neuenburg, MD
study director · Pharmacyclics LLC.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion